Specify a stock or a cryptocurrency in the search bar to get a summary
Amylyx Pharmaceuticals Inc
AMLXAmylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. Address: 43 Thorndike Street, Cambridge, MA, United States, 02141
Analytics
WallStreet Target Price
4.37 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures AMLX
Dividend Analytics AMLX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History AMLX
Stock Valuation AMLX
Financials AMLX
Results | 2019 | Dynamics |